Adjuvant therapy plays an increasingly important role in the treatment of stage III melanoma. Various drugs, including immunotherapies and targeted drugs, are currently used to reduce the risk of recurrence after surgical removal of the tumor. The latest results show that nivolumab as adjuvant treatment results in a longer relapse-free period compared to ipilimumab. Combinations of targeted drugs are also used in patients with a BRAF mutation, but it is not clearly established which regimen is most effective. The choice of treatment depends on several factors, including the genetic characteristics of the tumor and the general condition of the patient. Long-term follow-up confirms that adjuvant treatment can significantly improve treatment results. Research is ongoing to determine which patients benefit most from each type of treatment.